Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Xenon Pharma’s azetukalner shows 53% seizure reduction in trial By Investing.com
Xenon Pharmaceuticals’ azetukalner demonstrated a significant reduction in monthly seizure frequency, with a 53.2% decrease in the 25 mg group during its Phase 3 X-TOLE2 study. The positive trial results, presented at the American Academy of Neurology Annual Meeting, have led to a 70% surge in the company’s stock over the past year and raised approximately $747.5 million in a recent public offering, extending its cash runway. Xenon plans to submit a New Drug Application to the FDA in Q3 2026 for azetukalner, a KV7 potassium channel opener.